Q3 EPS Estimate for Avalo Therapeutics Lowered by Analyst

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Avalo Therapeutics in a report issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.58) per share for the quarter, down from their previous forecast of ($0.37). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($2.58) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.76) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.41) EPS.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25).

Several other brokerages also recently weighed in on AVTX. Mizuho increased their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Bank of America started coverage on shares of Avalo Therapeutics in a research report on Friday, June 12th. They set a “buy” rating and a $35.00 price objective for the company. Guggenheim set a $48.00 target price on shares of Avalo Therapeutics and gave the stock a “buy” rating in a research note on Friday. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They issued an “outperform” rating and a $38.00 target price for the company. Finally, BTIG Research reaffirmed a “buy” rating and issued a $58.00 target price on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Avalo Therapeutics Trading Up 7.9%

NASDAQ:AVTX opened at $19.77 on Tuesday. The firm has a market cap of $1.06 billion, a P/E ratio of -4.52 and a beta of 0.80. The stock’s 50 day simple moving average is $17.34 and its 200-day simple moving average is $16.33. Avalo Therapeutics has a 12-month low of $8.29 and a 12-month high of $24.27.

Hedge Funds Weigh In On Avalo Therapeutics

A number of large investors have recently made changes to their positions in AVTX. Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics in the second quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics during the third quarter worth about $143,000. AlphaCentric Advisors LLC purchased a new position in Avalo Therapeutics in the first quarter valued at about $174,000. Jump Financial LLC purchased a new position in Avalo Therapeutics in the fourth quarter valued at about $238,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Avalo Therapeutics during the 4th quarter valued at approximately $274,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.46% of the company’s stock.

Key Stories Impacting Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $30 price target, implying potential upside from recent trading levels. Bank of America Securities also reaffirmed its Buy rating, providing continued support for the company’s longer-term outlook. Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics
• Neutral Sentiment: A recent review highlighted Avalo’s widening losses alongside better-than-expected earnings-per-share trends, raising the possibility that management’s strategic changes could eventually improve performance. However, the company remains unprofitable and the turnaround is not yet established. Do Avalo Therapeutics’ Widening Losses But Better EPS Reveal a Turning Point in Strategy?
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across every listed period. Its FY2026 loss estimate widened to $2.76 per share from $2.02, while its FY2027 loss estimate widened to $2.41 from $1.78. Quarterly estimates for Q3 2026 through Q4 2027 were also reduced, signaling expectations for prolonged cash-burn and weaker profitability. HC Wainwright Cuts Avalo Therapeutics Price Target to $30

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.